MENU
CLOSE

Never miss a dose of ULTOMIRIS®!

Sign up for our free text-based reminder service

FRIDAY
8:00AM

Reminder - Your ULTOMIRIS (ravulizumab-cwvz) infusion is scheduled for today

Introducing our free text-based reminder service for people who are receiving ULTOMIRIS! To enroll:

  • Sign up and select your reminder times, based on your dosing schedule
  • Receive alerts when it’s time for your next infusion
  • It’s easy, convenient, and free!

Terms and Conditions & PRIVACY NOTICE

ULTOMIRIS Reminders SMS/MMS Terms and Conditions

By clicking "Submit" below, you are requesting to sign up for ULTOMIRIS Infusion Reminder SMS/MMS text messages. You will receive a confirmation code message at the number entered above, to confirm that you have requested such reminders. Text ‘HELP’ for technical questions. To stop receiving messages, you can reply "STOP" at any time to the reminder text messages.

There is no fee from Alexion Pharmaceuticals for the reminder text messages. However, your mobile service provider may charge for receipt of text messages including ULTOMIRIS infusion reminder messages. You should obtain information about any such charges from your mobile service provider. Such charges, if any, would likely be billed and payable to your mobile service provider or deducted from your prepaid account.

  1. Data obtained from you in connection with this SMS/MMS service may include your cell phone number, your carrier’s name, your time zone, and the times you submit at which you wish to receive reminder text messages. We will use this information to contact you and to provide the services you request from us.
  2. For information on data collection and use please read our full corporate Privacy Notice https://alexion.com/Legal#privacynotice.
  3. While the ULTOMIRIS Infusion Reminder text message service is intended to help patients remember to attend their infusion appointments, it is ultimately the responsibility of the patient to remember to attend their appointments.  By agreeing to these Terms and Conditions, you agree that neither Alexion nor any mobile service provider will be liable for any failure in transmission, receipt, or usability of any ULTOMIRIS Infusion Reminder text messages, regardless of the nature, cause or frequency of such failed transmission, receipt, or usability
  4. Alerts sent via SMS/MMS may not be delivered if the mobile phone is not in range of a transmission site, or if sufficient network capacity is not available at a particular time. Even within a coverage area, factors beyond the control of the wireless carrier may interfere with message delivery, including the customer’s equipment, terrain, proximity to buildings, foliage, and weather. You should be aware of the quality of mobile service available in a particular area when determining whether to rely on ULTOMIRIS Infusion Reminder text messages to attend your infusion appointments. 
  5. The service is available on U.S. carriers.
  6. ULTOMIRIS infusion reminder message frequency may vary depending on user input. Users can unsubscribe from this service at any time by replying ‘STOP’ to any infusion reminder texts.
  7. For technical questions, text ‘HELP’ to any medication reminder text.

PRIVACY NOTICE – ULTOMIRIS Infusion Reminder Text Messages

Drafted: August 2024

WHO HAS DEVELOPED THE ULTOMIRIS INFUSION REMINDER TEXT MESSAGE REMINDER PROGRAM

The ULTOMIRIS Infusion Reminder Text Message program (the “Text Reminder Program” or the “Program”) has been developed by Alexion AstraZeneca Rare Disease Unit, 121 Seaport Blvd Boston, MA 02210; (“we”, “us”, “our”).

PURPOSE OF THE TEXT REMINDER PROGRAM

The main purpose of the Text Reminder Program is to help patients remember to attend their infusion appointments. 

DATA THE PROGRAM COLLECTS, WHY IT IS COLLECTED AND WHAT IT IS USED FOR

In order to use the Program as intended, users will be asked to provide the following information about themselves and their infusion dates:  Mobile phone number, time zone, infusion date reminder times and frequency of recurring infusion appointments. Use of the Text Reminder Program is voluntary.

Alexion will not obtain any information through this service other than the information the user provides. Aside from the mobile phone number, no information that can be used to identify you will be collected by Alexion or shared with us as a function of the program. 

CATEGORIES OF ENTITIES WITH WHOM WE MAY DISCLOSE YOUR INFORMATION

We grant access to your information only to the extent needed to perform business functions and require entities that receive your information to protect the confidentiality and security of such information.

We will not share or sell your personal information to third parties except in the following circumstances: 

  • We may disclose all of the information we collect in connection with a business transfer or sale, for example, as part of a sale, assignment, or transfer of a business or asset, or acquisition of or merger with another entity. In the event of such a transfer, the acquiring entity would be limited in their use of the data we collect in the same manner set forth herein with respect to Alexion.  
  • We also may disclose any of the information we collect in response to requests from government or law enforcement agencies or where required or permitted by applicable laws, court orders, or government regulations, for example, in response to a subpoena or regulatory inquiry.
  • We may disclose all of the information we collect to protect rights and interests, for example, when needed for corporate audits, to investigate or respond to a complaint or threat, or to exercise our legal rights.

STORAGE OF DATA

All the information supplied as a result of the Text Reminder Program will be stored by Alexion on secure servers in the United States. This information may be transferred in accordance with any legal obligations as set forth above. If you opt out of the Text Reminder Program at a future time, you are removed from future notifications and your phone number and reminder selections will be deleted.

SECURITY OF YOUR DATA

We endeavor to ensure your information is kept confidential and secure and its use is limited to the purposes specified herein. We have implemented privacy and security controls designed to help protect your data. Please note, however, that no security measures are 100% effective, and we cannot guarantee absolute security of your data.

CONTACT DETAILS 

You may request access to the information held about you, to correct any mistakes or to request deletion of your information or withdraw your consent to certain types of processing of your information via email at privacy@alexion.com. If such a request places Alexion in breach of obligations under applicable laws, regulations or codes of practice, then we may be forced to decline your request, but you may still be able to request that your information is blocked for further processing. You may also have a right to data portability to another entity under certain circumstances.

UPDATES

We reserve the right to amend this Privacy Notice at our discretion and at any time.

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

Show more Show less
Show less

What is the most important information I should know about ULTOMIRIS?

ULTOMIRIS is a medicine that affects your immune system and may lower the ability of your immune system to fight infections.

  • ULTOMIRIS increases your chance of getting serious meningococcal infections that may quickly become life-threatening or cause death if not recognized and treated early.
  1. You must complete or update meningococcal vaccine(s) at least 2 weeks before your first dose of ULTOMIRIS.
  2. If you have not completed your meningococcal vaccines and ULTOMIRIS must be started right away, you should receive the required vaccine(s) as soon as possible.
  3. If you have not been vaccinated and ULTOMIRIS must be started right away, you should also receive antibiotics for as long as your healthcare provider tells you.
  4. If you had a meningococcal vaccine in the past, you might need additional vaccines before starting ULTOMIRIS. Your healthcare provider will decide if you need additional meningococcal vaccines.
  5. Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: fever, fever with high heart rate, headache and fever, confusion, muscle aches with flu-like symptoms, fever and a rash, headache with nausea or vomiting, headache with a stiff neck or stiff back, or eyes sensitive to light.

Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection. Carry it with you at all times during treatment and for 8 months after your last ULTOMIRIS dose. Your risk of meningococcal infection may continue for several months after your last dose of ULTOMIRIS. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.

ULTOMIRIS is only available through a program called the ULTOMIRIS and SOLIRIS Risk Evaluation and Mitigation Strategy (REMS). Before you can receive ULTOMIRIS, your healthcare provider must: enroll in the REMS program; counsel you about the risk of serious meningococcal infections; give you information about the signs and symptoms of serious meningococcal infection; make sure that you are vaccinated against serious infections caused by meningococcal bacteria, and that you receive antibiotics if you need to start ULTOMIRIS right away and are not up to date on your vaccines; give you a Patient Safety Card about your risk of meningococcal infection.

ULTOMIRIS may also increase the risk of other types of serious infections, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Your child should receive vaccines against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) if treated with ULTOMIRIS. Certain people may be at risk of serious infections with gonorrhea.

Who should not receive ULTOMIRIS?

Do not receive ULTOMIRIS if you have a serious meningococcal infection when you are starting ULTOMIRIS.

Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever
  • are pregnant or plan to become pregnant. It is not known if ULTOMIRIS will harm your unborn baby.
    • Pregnancy Registry: There is a registry for pregnant women who take ULTOMIRIS to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking ULTOMIRIS, talk to your healthcare provider about how you can join this registry or you may contact the registry at 1-833-793-0563 or www.UltomirisPregnancyStudy.com to enroll.
  • are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.

Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.

If you have PNH and you stop receiving ULTOMIRIS, your healthcare provider will need to monitor you closely for at least 16 weeks after you stop ULTOMIRIS. Stopping ULTOMIRIS may cause breakdown of your red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: drop in your red blood cell count, tiredness, blood in your urine, stomach-area (abdomen) pain, shortness of breath, blood clots, trouble swallowing, and erectile dysfunction (ED) in males.

What are the possible side effects of ULTOMIRIS?

ULTOMIRIS can cause serious side effects including infusion-related reactions. Symptoms of an infusion-related reaction with ULTOMIRIS may include lower back pain, stomach (abdominal) pain, muscle spasms, changes in blood pressure, tiredness, feeling faint, shaking chills (rigors), discomfort in your arms or legs, or bad taste. Stop treatment of ULTOMIRIS and tell your healthcare provider right away if you develop these symptoms, or any other symptoms during your ULTOMIRIS infusion that may mean you are having a serious infusion-related reaction, including: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out.

The most common side effects of ULTOMIRIS in people treated for PNH are upper respiratory tract infection and headache.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ULTOMIRIS. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider right away if you miss an ULTOMIRIS infusion or for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

INDICATION

What is ULTOMIRIS?

ULTOMIRIS is a prescription medicine used to treat adults and children 1 month of age and older with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).

It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age.

Please see the full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious meningococcal infections.